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Abstract
 
Experimental autoimmune encephalomyelitis (EAE) is mediated by autoantigen-specific T cells
dependent on critical costimulatory signals for their full activation and regulation. We report
that the programmed death-1 (PD-1) costimulatory pathway plays a critical role in regulating
peripheral tolerance in murine EAE and appears to be a major contributor to the resistance of
disease induction in CD28-deficient mice. After immunization with myelin oligodendrocyte
glycoprotein (MOG) there was a progressive increase in expression of PD-1 and its ligand
PD-L1 but not PD-L2 within the central nervous system (CNS) of mice with EAE, peaking
after 3 wk. In both wild-type (WT) and CD28-deficient mice, PD-1 blockade resulted in ac-
celerated and more severe disease with increased CNS lymphocyte infiltration. Worsening of
disease after PD-1 blockade was associated with a heightened autoimmune response to MOG,
manifested by increased frequency of interferon 
 
 
 
–producing T cells, increased delayed-type
hypersensitivity responses, and higher serum levels of anti-MOG antibody. In vivo blockade of
PD-1 resulted in increased antigen-specific T cell expansion, activation, and cytokine produc-
tion. Interestingly, PD-L2 but not PD-L1 blockade in WT animals also resulted in disease
augmentation. Our data are the first demonstration that the PD-1 pathway plays a critical role
in regulating EAE.
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Introduction
 
Murine experimental autoimmune encephalomyelitis (EAE)
 
*
 
is a T cell–dependent disease model used to investigate the
pathophysiology of multiple sclerosis. In this model, anti-
gen-specific CD4
 
  
 
Th1 cells mediate inflammatory damage
in the central nervous system (CNS), with consequent de-
myelination, manifested clinically by progressive paralysis
(1). In addition to reacting with peptides derived from my-
elin constituents, these encephalitogenic T cells require
the delivery of positive secondary costimulatory signals for
their complete activation and generation of effector func-
tion (2–4).
In general, T cells are regulated by a number of nonmu-
tually exclusive mechanisms, including clonal deletion me-
diated by apoptosis, anergy, and/or by soluble factors such
as cytokines or by professional regulatory cells (5). Further-
more, negative signals delivered to activated T cells by reg-
ulatory costimulatory pathways are essential contributors to
these mechanisms, and therefore act as natural inhibitors for
effector T cell expansion (6). The prototypic molecule in
this class is cytotoxic T lymphocyte–associated antigen 4
(CTLA-4), expressed on T cells after their activation.
Blockade or deficiency of CTLA-4 leads to enhanced au-
toimmunity with augmentation of EAE (7). However, the
B7 ligands that bind CTLA-4 also serve to mediate positive
signals to the T cells through the ligation of CD28, which
has made it harder to capitalize on a therapeutic strategy for
the treatment of clinical disease by manipulating CTLA-4
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Abbreviations used in this paper:
 
 ANOVA, analysis of variance; CNS,
central nervous system; CTLA-4, cytotoxic T lymphocyte–associated an-
tigen 4; DTH, delayed-type hypersensitivity; EAE, experimental autoim-
mune encephalomyelitis; GFAP, glial fibrillar-associated protein; MOG,
myelin oligodendrocyte glycoprotein; PD-1, programmed death-1.T
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signaling. Recently, a novel negative regulatory molecule
and a new member of the B7-CD28 superfamily has been
described, termed programmed death-1 (PD-1; 8). This
molecule is found on activated CD4
 
  
 
and CD8
 
  
 
T cells,
and binds to two known ligands, PD-L1 (also termed B7-
H1) and PD-L2 (also termed B7-DC), found on APCs as
well as on diverse parenchymal cell types (9–11). Ligation of
the PD-1 receptor leads to diminished proliferation and IL-2
production, and induction of cell cycle arrest with CD8
 
 
 
T cells appearing to be more sensitive to this effect than
CD4
 
  
 
cells (12). PD-1–deficient animals develop diverse
autoimmune conditions, such as autoimmune cardiomyop-
athy (BALB/c background) and a lupus-like syndrome with
arthritis and nephritis (C57BL/6 background; 13, 14). It is
interesting that the precise autoimmune phenotype that de-
velops is dependent on the genetic background of the ani-
mal in which the deficiency is produced. The development
of an autoimmune phenotype in the absence of PD-1, rem-
iniscent of that of CTLA-4–deficient animals (15) though
less severe, led to the suggestion that this pathway may play
a central role in the maintenance of peripheral tolerance to-
ward autoantigens (16). Indeed, the parenchymal expression
of PD-1 ligands may play a critical role in regulating au-
toimmune responses in various target organs. In this study,
we used blocking antibodies to PD-1, PD-L1, and PD-L2
to investigate whether this pathway plays a role in the regu-
lation of EAE. Our data confirm the important role of this
costimulatory pathway in limiting inflammatory disease in
EAE, which appears to exert an effect on both CD4
 
  
 
and
CD8
 
  
 
cells and crucially plays a role in the resistance of dis-
ease induction in CD28-deficient animals. These data pro-
vide the rationale for developing a strategy for PD-1 ligation
as a therapy to limit disease in EAE and multiple sclerosis.
 
Materials and Methods
 
Mice.
 
Female WT or CD28-deficient C57BL/6 mice, and
WT or DO-11.10 TCR transgenic BALB/c mice were pur-
chased from The Jackson Laboratory and housed according to lo-
cal and National Institutes of Health (NIH) guidelines. All mice
were used at 6–8 wk of age.
 
EAE Induction with Myelin Oligodendrocyte Glycoprotein (MOG).
 
MOG peptide 35–55 (MEVGWYRSPFSROVHLYRNGK) cor-
responding to the murine sequence was synthesized and HPLC
purified by Quality Controlled Biochemicals. WT or CD28-defi-
cient C57BL/6 mice were immunized subcutaneously in the
flank with 200 
 
 
 
g MOG peptide in CFA (Sigma-Aldrich) and
injected intraperitoneally with 200 ng pertussis toxin (List Bio-
logical Laboratories Inc.) on the day of immunization and 2 d
later. EAE was scored as previously described (17) with a grade
between 0 (no disease) and 5 (death).
 
Antibodies.
 
The anti–mouse PD-1 mAb (J43, hamster IgG)
has been described (8). The anti–mouse PD-L1 mAb (MIH6, rat
IgG2a) and the anti–mouse PD-L2 mAb (TY25, rat IgG2a) were
also recently described (18). Specific binding of these antibodies to
their respective ligands has been demonstrated (19). Antibodies
were manufactured by Bioexpres Cell Culture Inc. and given in-
traperitoneally according to the following regimen: 500 
 
 
 
g on the
day of immunization and 250 
 
 
 
g on alternate days until day 10 af-
ter immunization. Delayed therapy consisted of the same dose reg-
 
imen but was administered from day 10 after immunization. Con-
trol hamster IgG (ICN Pharmaceuticals Inc.) and control rat IgG
(Sigma-Aldrich) were given according to the same protocol.
 
ELISPOT Analysis to Measure the Frequencies of MOG-reactive T
Cells.
 
The ELISPOT assay was adapted to measure IFN-
 
 
 
–
secreting cells. ELISAspot plates (Cellular Technology Limited)
were coated with a capture antibody against IFN-
 
  
 
(clone R4-
6A2; BD Biosciences) in PBS and left overnight at 4
 
 
 
C. The
plates were blocked with 1% BSA-PBS for 1 h and then washed
with PBS. Between 5 and 10 
 
  
 
10
 
5 
 
splenocytes were added to
each well in 100 
 
 
 
l RPMI 1640 medium containing 10% fetal
calf serum (Sigma-Aldrich), 2 mM 
 
l
 
-glutamine, 100 U/ml peni-
cillin/streptomycin (BioWhittaker), and 50 
 
 
 
M 2-mercaptoetha-
nol (Sigma-Aldrich). Control wells contained responder spleno-
cytes plus medium alone. Cells were also tested in triplicate wells
against concanavalin A (Sigma-Aldrich) and different concentra-
tions of MOG peptide. After 48 h, the plates were washed and a
biotinylated detection antibody (clone XMG1.2; BD Biosciences)
was added and the plates were left for overnight incubation at
4
 
 
 
C. After further washing, horse radish peroxidase–conjugated
avidin (DakoCytomation) was added for 2 h at room temperature.
Development was with AEC (Sigma-Aldrich). The resulting spots
were counted on a computer-assisted ELISASpot Image Analyzer
(Cellular Technology Limited). The frequencies were then ex-
pressed as cytokine-producing cells per million splenocytes.
 
Histology.
 
Spinal cords and brains were harvested on days 14–
21 after immunization and snap frozen in optimal cutting tem-
perature compound. 4–10-
 
 
 
m thick sections were cut, fixed in
acetone, stained using the avidin-biotin technique (Vector Labo-
ratories), and counterstained with hematoxylin. Antibodies used
were anti-CD4 (clone H129.19), anti-CD8 (clone 53-6.7; BD
Biosciences), anti-F4/80 (clone CI:A3-1; Caltag Laboratories),
anti–PD-1 (J43), anti–PD-L1 (MIH6), and anti–PD-L2 (TY25).
Isotype-matched control IgG and omission of the primary anti-
body served as negative controls. Each specimen was evaluated at
three different levels of sectioning.
For dual staining of resident CNS cells, spinal cords were sec-
tioned at 20 microns and incubated with anti–PD-L1, anti–PD-
L2, anti–glial fibrillar-associated protein (GFAP; cocktail of
clones 4A11, 1B4, and 2E1; BD Biosciences), and FITC-conju-
gated isolectin IB4 (LB4, from Griffonia simplicifolia; Molecular
Probes) for 12 h. Sections were washed and incubated with ap-
propriate fluorochrome-conjugated secondary antibodies, Alexa
488 (green) or Alexa 594 (red; Molecular Probes). Sections were
analyzed using an immunofluorescence microscope equipped
with image analysis systems.
 
Adoptive Transfer of DO11.10 TCR Transgenic T Cells and Anti-
OVA Response.
 
To investigate the effect of PD-1 blockade on
antigen-specific T cells, adoptive transfer of OVA-specific
DO11.10 TCR transgenic T cells was performed as previously
described (6, 20, 21). In brief, splenocytes from DO11.10 mice
containing 3 
 
  
 
10
 
6 
 
CD4
 
  
 
KJ1-26
 
  
 
T cells were injected intrave-
nously into nonirradiated BALB/c mice. 24 h later, 100 
 
 
 
g
OVA
 
323–339 
 
peptide in IFA was injected subcutaneously. 4 d later,
the animals were killed and the draining lymph nodes were col-
lected. The extent of expansion of the CD4
 
  
 
KJ1-26
 
  
 
population
was compared in animals treated with no OVA challenge, those
immunized with OVA and receiving control hamster IgG, and
those receiving immunization and anti–PD-1 mAb. Two to three
mice were used in each group per experiment. Results are ex-
pressed as the absolute number of CD4
 
  
 
KJ1-26
 
  
 
cells for one
representative experiment. Furthermore, isolated lymphocytes
were incubated in vitro with 1 
 
 
 
g/ml OVA
 
323–339 
 
peptide for 72 h,T
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and then stained for intracellular cytokine expression and acti-
vation markers. Results are expressed as the number of CD4
 
 
 
KJ1-26
 
  
 
cells expressing the markers.
 
Flow Cytometry.
 
Splenocytes or lymph node cells were
stained with antibodies to the activation marker CD25 and intra-
cellular cytokines (IFN-
 
 
 
, IL-4, IL-5, and IL-10; BD Bio-
sciences). Cells were analyzed on a FACSCalibur™ (Becton
Dickinson) using CELLQuest™ software (Becton Dickinson).
 
Measurement of Delayed-type Hypersensitivity (DTH) and Anti-
MOG Antibodies.
 
In each group, three to five animals were
used at day 14 after immunization for measurement of DTH re-
actions and measurement of serum anti-MOG antibodies. DTH
was assessed by measurement of the thickness of the footpad or
ear, followed by intradermal injection on one side of MOG pep-
tide (50 
 
 
 
g in 50 
 
 
 
l PBS) or on the contralateral side with an
equal volume of PBS. After 48 h the change in skin thickness was
measured and the net increase (with MOG peptide 
 
  
 
control
PBS) was calculated. Anti-MOG antibodies were measured by
ELISA as previously reported (17) and their titre was expressed as
the absorbance at 450 nm.
 
Results
 
PD-1 and PD-L1 Expression Is Increased over Time in the
CNS of Animals with EAE.
 
Animals with EAE were
killed at different time points up to 1 mo from the time of
immunization. Sections of their spinal cords were stained
for PD-1 and its ligands PD-L1 and PD-L2. Staining re-
vealed an increased level of PD-1 expression on infiltrating
cells beginning in the second week, peaking at the third
week, and persisting for the 4 wk studied (Fig. 1 a). Ex-
pression of PD-L1 increased over a similar time period, al-
though we found no PD-L2 staining in the brains until day
30 when only minimal staining was observed (Fig. 1 a).
This time course of expression of both PD-1 and PD-L1
closely follows that of clinical disease in mice with EAE:
peaking in the second to third weeks (Fig. 2 a). Further-
more, using dual color staining we demonstrated PD-L1
but not PD-L2 expression on resident astrocytes (colocal-
ized with anti-GFAP mAb) and microglial cells (colocal-
ized with lectin IB4), in brains of animals with EAE at 20
and 30 d, respectively (Fig. 1 b).
 
Blockade of PD-1 Results in Accelerated and More Severe Dis-
ease in WT Mice.
 
After in vivo blockade using anti–PD-1
mAb, a more rapid and higher grade disease was observed
in animals immunized with MOG 33–55 peptide (Fig. 2
a). Compared with control animals treated with either
control hamster IgG or carrier (PBS), there was a statisti-
cally significant increase in disease scores in the anti–PD-1
mAb-treated WT animals (mean maximal score 2.94 
 
 
 
1.3 vs. 1.75 
 
  
 
1.0 in control animals, P 
 
  
 
0.005 by two-
tailed Mann-Whitney U test). Overall disease incidence
Figure 1. Expression of PD-1, PD-L1, and PD-L2 in the CNS of mice with EAE. (a) Time course of expression of PD-1, PD-L1, and PD-L2. Immu-
nohistochemistry for PD-1, PD-L1, and PD-L2 expression in spinal cord sections from animals with EAE at different time points after immunization for
up to 1 mo. The numbers above each plate represent the time after immunization when the animals were killed and the sections were stained. There is a
progressive increase in the PD-1 and PD-L1 expression, which appears to peak by day 21 and begin to decline thereafter, mirroring the clinical tempo of
disease ( 100), whereas there is no PD-L2 staining until day 30 when it appears minimally. (b) Expression of PD-L1 on resident brain cells during EAE.
Confocal immunohistochemistry demonstrating expression of PD-L1 on astrocytes (costained with GFAP on day 20 of EAE) and microglia (costained
with lectin IB4 on day 30 of EAE; all  40). No expression of PD-L2 was found on resident brain cells.T
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was similar in both groups (89%), although the PD-1
blockade group had an earlier onset compared with con-
trol, so that at 13 d after immunization the PD-1 blockade
group had an incidence of 89% whereas the control group
only had 25% incidence (P 
 
  
 
0.0075, 
 
 
 
2 test). By con-
trast, the delayed PD-1 blockade (beginning 10 d after im-
munization and continuing for 10 d) demonstrated no
augmentation of disease compared with control Ig–treated
animals (Fig. 2 b).
 
Blockade of PD-L2 but not PD-L1 Results in More Severe
Disease in WT Mice.
 
We then sought to examine the ef-
fects of blockade of the PD-1 ligands, PD-L1 or PD-L2,
on disease course. In vivo administration of anti–PD-L2
mAb in WT mice resulted in disease augmentation com-
pared with control Ig–treated animals (mean maximal
score 4.125 
 
  
 
0.27 vs. 2.64 
 
  
 
0.5 in controls, P 
 
  
 
0.030
by two-tailed Mann-Whitney U test), although the overall
incidence and time of onset were similar in the two groups
(Fig. 2 c). By contrast, administration of anti–PD-L1 mAb
had no effect on disease severity compared with controls
(Fig. 2 c).
 
CD28-deficient Mice Are Protected from Disease Induction,
but Lose Their Disease Resistance after PD-1 Blockade.
 
We
and others have previously reported that CD28-deficient
mice are resistant to disease induction (3, 22) but are capa-
ble of developing disease after a more potent immune
stimulus, such as double immunization or after CTLA-4/
B7 blockade (3). After the PD-1 pathway blockade,
CD28-deficient mice developed moderately severe disease
(mean maximal disease score 2.07 
 
  
 
0.43 compared with
0.85 
 
  
 
0.37 in the control CD28-deficient group, P 
 
 
 
0.0006 by two-tailed Mann-Whitney U test; Fig. 2 d).
The cumulative incidence and time of onset in the PD-1
blockade and control groups were similar. These data
demonstrate that the disease resistance in CD28-deficient
animals is related in part to inhibitory signaling through
PD-1. Moreover, it is interesting to note that the mean
disease score achieved with PD-1 blockade was greater
than that achieved by CTLA-4 blockade previously re-
ported by our group (3).
 
PD-1 Blockade Results in Increased Frequency of IFN-
 
 
 
–pro-
ducing MOG-reactive T Cells and DTH Responses.
 
14 d af-
ter MOG immunization, splenocytes were isolated from
animals in each of the treatment groups and were assayed
by ELISPOT for IFN-
 
  
 
production in response to MOG
peptide. When compared with the control animals, those
treated with PD-1 blockade had a higher frequency of
IFN-
 
 
 
–producing MOG-reactive T cells in both WT
(Fig. 3 a; P 
 
  
 
0.017 by one-way analysis of variance
[ANOVA]) and CD28-deficient animals (Fig. 3 b; P 
 
 
 
0.0254 by one-way ANOVA). Moreover, in WT mice
there was a significant increase in DTH reaction in the an-
imals treated with anti–PD-1 mAb compared with con-
trols (Fig. 3 c; P 
 
  
 
0.0245 by two-tailed Mann-Whitney
U test).
 
PD-1 Blockade Increases anti-MOG Antibody Production.
 
Because PD-1 is also up-regulated on activated B cells (8)
and antigen-specific class-switched antibody production is
a T cell–dependent process, we measured anti-MOG IgG
antibody production in animals treated with anti–PD-1
mAb or control IgG. 14 d after immunization, serum was
obtained from the animals and anti-MOG antibodies were
measured by ELISA. In both WT and CD28-deficient an-
imals there was a significant increase in the level of anti-
MOG antibodies measured after the PD-1 blockade (Fig.
3 d).
Figure 2. EAE outcome in
animals treated with PD-1 path-
way blockade. The disease scores
for control and anti–PD-1–
treated animals  40 d of follow
up are shown, for WT mice with
early therapy (a) and delayed
therapy (b), and for CD28-defi-
cient mice (d). There is a highly
significant difference in disease
severity between the early ther-
apy and control groups (P  
0.0053 for WT and P   0.0074
for CD28-deficient mice by
two-tailed Mann-Whitney U
test). No difference was found
with delayed therapy. PD-L2
blockade also augmented disease
(P   0.03 compared with con-
trol by two-tailed Mann-Whit-
ney U test) whereas PD-L1
blockade had no effect (c).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
75
 
Salama et al.
 
Histology of Spinal Cords from Anti–PD-1–treated Animals
and Controls.
 
Histological examination of spinal cord sec-
tions from mice treated with anti–PD-1 or control IgG on
day 14 after immunization mirrored the clinical course
(Fig. 4). Compared with the control mice, both WT and
CD28-deficient mice treated with anti–PD-1 mAb exhib-
ited increased cellular infiltration into the CNS of CD4
 
 
 
and CD8
 
  
 
lymphocytes and F4/80
 
  
 
macrophages. Interest-
ingly, there was an excess of CD8
 
  
 
cells in the CNS of
mice treated with anti–PD-1 mAb, suggesting that the PD-1
pathway preferentially regulates encephalitogenic CD8
 
 
 
cells, in keeping with previous reports demonstrating
greater sensitivity of CD8
 
  
 
cells to PD-1–mediated sup-
pression (12).
 
The Effect of PD-1 Blockade on OVA-specific T Cell Re-
sponses.
 
Because ELISPOT frequencies of MOG-reac-
tive IFN-
 
 
 
–producing T cells were increased after PD-1
blockade in normal and CD28-deficient mice, we decided
to examine the effect of PD-1 blockade on T cell expan-
sion and production of Th1/Th2 cytokines using another
antigen-specific system. We used the adoptive transfer of
OVA-specific T cells from DO11.10 TCR transgenic mice
(6, 19, 20). Naive BALB/c mice were adoptively trans-
ferred with DO11.10 splenocytes and their responses after
Figure 3. T cell and antibody
responses to MOG in animals
treated with PD-1 blockade.
ELISPOT analysis from one rep-
resentative experiment, demon-
strating the frequency of MOG-
specific IFN- –producing T
cells at different concentrations
of antigen for WT (a) and
CD28-deficient animals (b). In
the WT group, anti–PD-1–
treated animals (solid bars) had a
higher frequency of MOG-spe-
cific IFN- –producing T cells at
all antigen concentrations com-
pared with controls (hatched
bars, *, P   0.017 by one-way
ANOVA). In the CD28-defi-
cient mice, a significant differ-
ence was also seen at higher anti-
gen concentrations (*, P  
0.0254 by one-way ANOVA).
(c) DTH measurement assessed
by an increase in footpad skin
thickness after intradermal injec-
tion with 50  g antigen. DTH
response was significantly greater
in the anti–PD-1–treated animals
than controls (*, P   0.0245 by two-tailed Mann-Whitney U test). (d) Serum level of anti-MOG antibodies obtained on day 14 after immunization were
greater in anti–PD-1–treated animals than controls in both WT and CD28-deficient animals (*, P   0.0476; **, P   0.0009 by two-tailed Mann-Whit-
ney U test).
Figure 4. Immunohistology
of the CNS in animals treated
with PD-1 blockade. Spinal cord
sections from WT and CD28-
deficient animals treated with
anti–PD-1 or control antibody
were obtained on day 14 after
immunization and stained with
anti-CD4, anti-CD8, and anti-
F4/80. There is a visible increase
in the number of CD4   and
CD8  T cells as well as the mac-
rophages (F4/80   cells) in the
anti–PD-1–treated mice, com-
pared with controls in both the
WT and CD28-deficient ani-
mals, more apparent in the
former ( 200).T
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immunization with OVA peptide and treatment with anti–
PD-1 mAb or control IgG were examined. The transferred
DO11.10 T cells were identified by using an anti-TCR
clonotypic mAb KJ1-26 (Fig. 5, a and b). Control nonim-
munized mice demonstrated that the CD4   KJ1-26 
DO11.10 T cells made up  0.7% of the lymph node cells
(corresponding to a total of 1.6   103 CD4  KJ1-26  cells;
not depicted). However, after immunization with OVA
peptide, there was a significant expansion of antigen-spe-
cific T cells in the draining lymph nodes. In the control
IgG–treated animals this reached 5.7   0.6   106 cells,
whereas in the anti–PD-1–treated animals this reached
91.8   20.9   106, reflecting a marked (16-fold) expansion
of antigen-specific T cells (Fig. 5 c; P   0.0001). Further-
more, a greater percentage of cells expressed the activation
marker CD25 (94.3   2.2% compared with 76.8   8.9%
in anti–PD-1–treated and control mice, respectively). Fi-
nally, PD-1 blockade resulted in a greater number of cells
producing both Th1 (IFN- : 16.7   0.8   105 vs. 5.7  
0.13   105, anti–PD-1 and control, respectively) and Th2
(IL-4: 46.49   7.08   105 vs. 4.98   1.46   105; IL-5:
32.37   17.9   105 vs. 0; and IL-10: 6.25   3.4   105 vs.
0) cytokines (not depicted).
Discussion
The outcome of T cell responses to their cognate anti-
gens is dependent on the balance between activating and
inhibitory signals (5, 23). PD-1 is a newly described mem-
ber of the CD28/CTLA-4 superfamily, which acts as a
negative regulator of activated T cells (8, 10, 16). PD-1–
deficient mice develop splenomegaly and autoimmunity in
the form of arthritis, nephritis, or cardiomyopathy, the
phenotype being dependent on their genetic background
(13, 14). Therefore, it has been suggested that the PD-1
pathway may serve as an important regulator of peripheral
tolerance (16). In this report we demonstrated that the PD-1
pathway serves to regulate the autoimmune, MOG-reac-
tive T cells in EAE. After PD-1 blockade a classical pattern
of EAE disease developed (with ascending paralysis), but
this was of greater severity than in control mice. In particu-
lar, this pathway appears to inhibit a population of CNS-
infiltrating T cells, which were minimally present in cord
sections of control EAE mice, but were more prominent in
those from anti–PD-1–treated animals. Furthermore, PD-1
blockade was associated with increased frequencies of au-
toreactive (MOG-specific) T cells, increased DTH re-
sponses to the autoantigen, and greater autoantibody pro-
duction. Finally, based on the anti-OVA response data, it
appears that the PD-1 pathway inhibits not only antigen-
specific T cell expansion, but also T cell activation and the
production of both Th1 and Th2 cytokines. It is therefore
not surprising that after PD-1 pathway blockade, EAE was
augmented. Interestingly, this occurred in both WT and
CD28-deficient animals, the latter normally being resistant
to disease induction, after a single immunization with
MOG (3, 22). We previously demonstrated that CTLA-4
blockade in CD28-deficient animals resulted in mild to
modest disease induction (3), although the mean maximum
disease score reached after CTLA-4 blockade was lower
than that after PD-1 blockade. CD28-deficient T cells re-
main capable of up-regulating PD-1 after activation (not
depicted), and together these data suggest that in the ab-
sence of CD28 signaling, T cell activation is largely kept in
check by the PD-1 inhibitory pathway, as well as by the
CTLA-4 pathway. This is also in keeping with recently
published data demonstrating a greater inhibitory effect of
the PD-1 pathway on T cells activated through the ICOS
rather than CD28 costimulatory pathway (24). Interest-
ingly, delayed PD-1 blockade had no effect on disease se-
verity in WT mice, suggesting that once primed, effector T
cells are less susceptible to inhibitory PD-1 signals. How-
ever, our model is one of progressive disease and the role of
PD-1 on effector T cells and maintenance of tolerance may
best be demonstrated in a relapsing-remitting disease model
(25), as has been shown for CTLA-4 (25, 26).
PD-L1 is expressed not only on haemopoietic APCs but
also on parenchymal cells, such as cardiac myocytes, renal
Figure 5. Effect of PD-1 blockade on
antigen-specific cells in vivo. DO11.10
TCR Tg cells (3   106 cells per mouse)
were transferred into BALB/c mice. 4 d
after priming with OVA peptide, the
draining lymph nodes were collected
and the number of OVA-specific (KJ1-
26 ) CD4  T cells was measured. (a)
Flow cytometry plot of CD4  KJ1-26 
cells from control IgG–treated animals,
demonstrating that 1.54% of lymph
node cells were TCR transgenic CD4 
T cells. (b) By comparison, in the anti–
PD1–treated animal 2.5% of lymph
node cells were TCR transgenic. (c)
Calculating the absolute numbers of
TCR transgenic cells demonstrates a sig-
nificant increase in KJ1-26   CD4   T
cells in the anti–PD-1–treated animals
compared with controls (P   0.0001 by
two-tailed Mann-Whitney U test).T
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tubular cells, and microvascular endothelial cells as well as
cancer cell lines (11, 27, 28). By contrast, PD-L2 has more
limited expression, predominantly on cytokine-activated
macrophages and dendritic cells (11, 18). These patterns of
expression may allow for the termination of an immune re-
sponse in inflamed tissues, limiting organ damage, or in tu-
mors allowing for immune evasion (27). We have found
abundant expression of PD-L1 but minimal PD-L2 expres-
sion in the brains of animals with EAE. Moreover, we
demonstrated only PD-L1 expression on resident brain
cells. However, our in vivo data demonstrate that PD-L2
and not PD-L1 blockade augments disease, suggesting that
the PD-1–mediated regulation might be occurring in the
peripheral lymphoid organs and not within the brain itself.
Further confirmation of this hypothesis will require the
generation of bone marrow chimeras from WT and PD-
1L–deficient animals, which is part of ongoing work. Al-
ternatively, there remains the remote possibility that the
anti–PD-L2 mAb might be providing a “positive” signal to
dendritic cells, enhancing their immunostimulatory abili-
ties, as has been demonstrated for certain IgM antibodies
(29). Interestingly, these findings are in contrast to those in
the NOD diabetes model (19), in which PD-1 and PD-L1
but not PD-L2 blockade precipitated disease and insulitis.
The disparate effects in these models may reflect differences
between spontaneous and induced autoimmune diseases.
Notably, they are reminiscent of the disparate effects of
B7-1 versus B7-2 blockade in EAE and autoimmune dia-
betes (30, 31).
Although the autoimmune phenotype of the PD-1–defi-
cient mice as well as other in vitro data suggest that the
PD-1 pathway is inhibitory (13, 14), conflicting data as to
its role exist. Some reports have suggested that PD-L1 can
enhance T cell proliferation and IL-10 production (9), and
PD-L2 can promote proliferation of naive T cells and Th1
cytokine production (32). Moreover, ligation of PD-L1
may costimulate T cells (33) and ligation of PD-L2 by
cross-linking IgM antibodies may activate dendritic cells
and augment T cell responses (29). Thus, an alternative ex-
planation for our findings might be that the antibodies used
could be stimulatory in vivo. However, several pieces of
evidence indicate that the IgG antibodies used in our ex-
periments do not appear to be mediating their effects by
stimulating T cell responses. In vivo, Fab fragments of anti–
PD-1 mAb (J43) augment immune responses to the same
extent as the whole antibody (unpublished data) and in
vitro, the anti–PD-L1 (MIH6) and anti–PD-L2 (TY25)
whole antibodies and Fab fragments block the suppression
of proliferative responses of preactivated T cells by PD-L1
and PD-L2 transfectants, respectively (unpublished data).
Moreover, the disparate effects of anti–PD-L1 and anti–
PD-L2 mAbs in EAE and NOD diabetes (19) argue against
the antibodies acting agonistically.
In conclusion, our data demonstrate an important role
for immune regulation by PD-1 in EAE, an induced au-
toimmune disease. The challenge now is to manipulate this
pathway therapeutically and allow termination of ongoing
autoimmune reactions by stimulating the PD-1 pathway.
Indeed, a recent report using a PD-L1 fusion protein in the
context of an alloimmune response demonstrated that such
a strategy is feasible and beneficial (34).
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